Compare D R Horton Inc (DHI) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Enveric Biosciences Inc — how do they compare? D R Horton Inc trades at $151.35 (market cap $42.53B), while Enveric Biosciences Inc trades at $1.32 (market cap $5.32M). The key difference: D R Horton Inc is far larger — about 7994.4× Enveric Biosciences Inc's market cap, and D R Horton Inc pays a 1.2% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| DHI | ENVB | |
|---|---|---|
Market Cap | $42.53B | $5.32M |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $17.40 |
52-Week Low | $129.82 | $1.28 |
Enterprise Value | $47.25B | $408.82K |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $148.85, down 1.8% over 24 hours, with a bearish technical signal from moving averages but oversold RSI levels. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025, with revenue declining to $34.25 billion in 2025. Analyst consensus is split between Buy and Hold ratings, with a $164.71 price target suggesting potential upside. Recent news highlights housing market headwinds from rising mortgage rates but also potential support from new legislation.
DHI presents a cautious opportunity with attractive valuation multiples (P/E 13.98, P/S 1.32) and a stable dividend, but faces risks from housing affordability pressures and volatile cash flows. Investors should weigh the company's scale and market position against macroeconomic challenges in the homebuilding sector.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
